Colossal Biosciences vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Colossal Biosciences is the world's first de-extinction company; $555M raised, $10.2B decacorn valuation; targeting woolly mammoth embryos by 2026, dire wolves already created Mar 2025.
About
Colossal Biosciences is the world's first commercial de-extinction and genomic engineering company, applying CRISPR gene editing and synthetic biology to resurrect extinct species and restore ecological balance. Founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal is simultaneously pursuing the de-extinction of the woolly mammoth, the Tasmanian thylacine, the dodo bird, the dire wolf, and the bluebuck antelope — building the scientific and technological infrastructure to produce living specimens of each. The company's Dallas, Texas headquarters anchors a multi-disciplinary team spanning computational biology, developmental biology, reproductive science, and conservation ecology.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.